SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is trending amid community discussion around its potential as 'the new Bitcoin' and increased institutional interest, particularly following investments from figures like the Winklevoss twins. Conversations highlight ZEC's privacy features and limited supply, with some suggesting a significant shift from Bitcoin to Zcash. Bullish sentiment is tempered by concerns about volatility and potential corrections.

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is trending as the crypto community discusses its potential breakout, referencing patterns observed in Zcash's previous run. Bullish sentiment is fueled by the anticipation of a government reopening and the LTCN ETF, with some eyeing price targets in the hundreds. Technical analysis chatter includes inverted head and shoulders patterns and golden cross formations, suggesting a possible surge if key resistance levels are breached.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+ and TMTG News. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

DJT is trending amidst heightened speculation and community chatter surrounding the release of Epstein files and their potential implications for the company and its figureheads. The community is actively dissecting alleged connections and potential fallouts, while some voice concerns about the company's financial performance. Political narratives and partisan bickering continue to fuel the conversation around the stock.

XPeng, Inc. engages in the design, development, manufacture, and marketing of smart electric vehicles. Its products are environmentally friendly vehicles, namely an SUV (the G3) and a four-door sports sedan (the P7). It also provides a range of services to the clients, including supercharging service, maintenance service, ride-hailing service and vehicle leasing service. The company was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPEV is trending as investors discuss upcoming earnings and the company's potential for profitability, with some anticipating a positive report. Community members are also highlighting XPEV's expansion into robotics and AI, seeing it as more than just an EV company and comparing its progress to competitors. Bullish sentiment seems to be growing, although some concerns about cash flow and potential dilution remain.

The community has officially TAKEN OVER $HIPPO - after the dev threw in the towel! The cutest $HIPPO on SUI is now powered by a full CTO. No cats, no dogs. Only $HIPPO, driven by the people, for the people! $HIPPO is ready to break out stronger than ever!  Su Deng is the cutest $HIPPO on SUI, bringing $HIPPO to the world of memes.  $HIPPO - No cats, no dogs Only hippo!  We are donating a % of our profits to wildlife needs across the world. Starting with support for Khao Kheow Open Zoo, the zoo that houses Moo Deng

sudeng

HIPPO (sudeng) is experiencing increased attention, with community members actively discussing potential pumps and anticipating a comeback. The conversation includes speculation about market influences, recent price drops, and comparisons to other meme coins in the SUI ecosystem, generating both excitement and questions about its future.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax is trending amid discussions about its partnership with Vaxart for an oral COVID-19 vaccine, a potential game-changer in vaccine delivery. The community is weighing the implications of institutional ownership, share buybacks, and a proxy fight involving Deep Track Capital. Some are speculating on potential buyout scenarios and the future direction of Dynavax's strategic partnerships.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

Red Cat Holdings is trending amidst lowered sales guidance for 2025, despite a recent revenue beat and expansion of a U.S. Army contract, triggering debate about management's credibility and future prospects. Community discussions revolve around the impact of government delays and the potential for a strong 2026, with some expressing concerns about the company's leadership and others seeing a buying opportunity. The drone sector's overall growth potential remains a key talking point.

Tidal Trust II - YieldMax TSLA Option Income Strategy ETF

YieldMax TSLA Option Income Strategy ETF

TSLY is trending due to news of a potential reverse split, leading to discussions about its impact on the ETF and investor returns. Community members are also weighing in on recent dividend payouts and strategizing around reinvestment and potential trading opportunities. Some are expressing concerns about NAV erosion and comparing TSLY to other high-yield ETFs.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

MannKind (MNKD) is trending due to community discussion around the company's leadership and strategic decisions, particularly regarding CEO Mike Castagna. Debate centers on past agreements, product commercialization, and the potential for a merger or acquisition. Bullish sentiment exists based on analyst upgrades and future growth prospects, while others express concerns about the company's performance and direction.

Dutch Bros, Inc. engages in operating and franchising drive-thru shops that focus on handcrafted beverages. It operates through the Company-Operated Shops, and Franchising and Other segments. The Company-Operated Shops segment consists of coffee shop sales to customers. The Franchising and Other segment is involved in bean and product sales to franchisees and includes the initial franchise fees, royalties, and marketing fees. The company was founded by Travis Boersma and Dane Boersma in 1992 and is headquartered in Tempe, AZ.

Dutch Bros Inc - Ordinary Shares - Class A

Dutch Bros Inc

Dutch Bros is trending amidst discussions about upcoming earnings and its potential growth compared to competitors like Starbucks. Community members are weighing factors such as tariff reductions, expansion strategies, and consumer spending habits, while some debate the stock's valuation and potential price movement. Bullish sentiment is building towards earnings, though concerns about consumer spending and the overall economic climate remain.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Anavex Life Sciences (NASDAQ:AVXL) Reaches New 12-Month Low - Here's Why

Anavex Life Sciences (NASDAQ:AVXL) Reaches New 12-Month Low - Should You Sell...

Anavex Shares Fall 35% After Negative EU Trend Vote On Alzheimer's Drug

(RTTNews) - Anavex Life Sciences Corp. (AVXL) dropped 35.15% to $3.69, down $2.00, after regulatory updates revealed that the Committee for Medicinal Products for Human Use - CHMP issued a negative...

<ul class="summary-bullets"><li>CHMP provides recommendations to the EMA on human medicines, which the agency uses to approve or reject a drug.</li><li>However, the drug didn’t feature on the list of medicines for which applications were withdrawn following a meeting with the committee.&nbsp;</li><li>Anavex confirmed on Friday that it was informed by the CHMP of a negative trend vote on its application for Blarcamesine following its oral explanation.</li></ul>Shares of Anavex Life Sciences (AVXL) slumped 45% in the premarket session on Friday after a European Medicines Agency (EMA) committee did not recommend a much-awaited approval for the company’s Alzheimer’s drug Blarcamesine.Retail investors were looking forward to the Committee for Medicinal Products for Human Use’s opinion on the drug after it placed Blarcamesine on its agenda for oral explanations and regulatory review during the session scheduled from Nov. 10 to Nov.13, with the oral explanation held behind closed doors on Nov. 11.<h2 class="st-heading-2">CHMP Avoids Recommendation For Blarcamesine</h2>The CHMP <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-november-2025">released</a> its meeting highlights on Friday and recommended approval for ten new medicines, but Blarcamesine did not feature on the list. CHMP provides recommendations to the EMA on human medicines, which the agency uses to approve or reject a drug. The lack of a positive recommendation dampens chances for an EMA approval for the drug.However, the drug also didn’t feature on the list of medicines for which applications were withdrawn following a meeting with the committee.Anavex <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/11/14/3188222/29248/en/Anavex-Life-Sciences-Provides-Regulatory-Update-on-Blarcamesine-for-Early-Alzheimer-s-Disease.html">confirmed</a> on Friday that it was informed by the CHMP of a negative trend vote on its application for Blarcamesine following its oral explanation. The committee is expected to adopt a formal opinion on the application at its December meeting, the company said, while adding that it intends to request a re-examination of the committee’s opinion.Anavex submitted an application to the EMA for Blarcamesine in November 2024 based on data from a Phase 2b/3 trial, and the agency subsequently accepted it in December. If the application is approved, it would allow Blarcamesine to be marketed in all EU member states.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around<a href="https://stocktwits.com/symbol/AVXL"> AVXL stock </a>stayed within the ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.AVXL stock is down 47% this year and by 29% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/avadel-gets-acquisition-proposal-from-lundbeck-weeks-after-inking-agreement-with-alkermes/cLPQetHRE4T">Avadel Gets Acquisition Proposal From Lundbeck Weeks After Inking Agreement With Alkermes</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

AVXL Shares Slump Pre-Market After EMA Committee Fails To Recommend Approval For Alzheimer’s Drug

The CHMP released its meeting highlights on Friday and recommended approval for ten new medicines, but Blarcamesine was not included in the list.

Equity

The CHMP released its meeting highlights on Friday and recommended approval for ten new medicines, but Blarcamesine was not included in the list.


<ul class="summary-bullets"><li>The selloff comes as blarcamesine completed its oral explanation during the EMA’s Nov. 10–13 review window.</li><li>The therapy reached this stage after progressing through the Day-120 and Day-180 questions earlier this year.</li><li>Investors are watching for any CHMP update following recent data showing a slowing of cognitive decline.</li></ul>Anavex Life Sciences shares posted their steepest single-day drop in nearly two years on Thursday as investors braced for a key regulatory moment in Europe for its Alzheimer’s drug candidate, blarcamesine. The selloff comes as the therapy completed Oral Explanation Week at the European Medicines Agency (EMA), a step that typically signals regulators have unresolved questions late in the review.<h2 class="st-heading-2">Blarcamesine Completes EMA Oral Review Week</h2>The Committee for Medicinal Products for Human Use, or CHMP, placed blarcamesine on its agenda for oral explanations and regulatory review during the session scheduled from Nov. 10 to Nov.13, with the oral explanation held behind closed doors on Nov. 11. Oral explanations are not standard for smooth applications and they appear only when CHMP wants direct clarification before issuing an opinion, according to a&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://seekingalpha.com/article/4842401-anavex-stock-nears-alzheimers-decision-with-limited-pipeline-offsets-atm-overhang">report</a> by Seeking Alpha.The drug’s EU dossier has progressed through the formal review stages over the past year, with Day-120 questions in April and Day-180 outstanding issues in September, at which point the CHMP noted that major objections remained. With the November session now concluded, investors are watching for any outcome in the committee’s published meeting highlights.<h2 class="st-heading-2">Recent Clinical Signals Added To Investor Focus</h2>In September, Anavex r<a href="https://stocktwits.com/news-articles/markets/equity/anavex-life-sciences-stock-rises-after-experimental-alzheimers-drug-slows-cognitive-decline/chwK3gqRdt9">eported new clinical findings</a> showing cognitive stabilization over 48 weeks in a precision-medicine subgroup of patients with early Alzheimer’s disease. Participants taking 30 mg once daily blarcamesine showed barely detectable cognitive decline across standard Alzheimer’s scales, and the company said the drug produced an 84.7% reduction in decline versus placebo on one neuropsychological test.The company is also testing blarcamesine in Parkinson’s disease dementia and Rett syndrome, expanding its pipeline beyond Alzheimer’s.<h2 class="st-heading-2">Analysts Still See A Possible Path To Conditional Approval</h2><a href="https://stocktwits.com/news-articles/markets/equity/anavex-life-sciences-stock-sparks-retail-banter-on-hopes-of-ema-conditional-nod-for-alzheimer-s-drug-big-pharma-tie-up/cLGP67oR3po">A report last month</a> from Spirit of the Coast Analytics said blarcamesine remains a candidate for conditional approval, noting that the Phase 2b/3 study had a modest sample size and missed one co-primary endpoint but showed statistically strong results on other measures, with supporting long-term durability data. The report highlighted that the EMA often opts for conditional approval for diseases with major unmet needs when safety is favorable.<h2 class="st-heading-2">Stocktwits Users Debate Path Forward</h2>On Stocktwits, retail sentiment for Anavex was ‘extremely bullish’ amid a 137% jump in 24-hour message volume.<figure class="image"><img style="aspect-ratio:964/146;" src="https://news.stocktwits-cdn.com/avxl_ss_jpg_4b62ea4809.webp" alt="avxl ss.jpg" width="964" height="146"><figcaption>AVXL sentiment and message volume as of November 14 | Source: Stocktwits</figcaption></figure>One Stocktwits user argued that blarcamesine has an underappreciated advantage because it targets the same biological pathway that has long been pursued in the longevity and biohacking spaces, citing fasting, rapamycin, and other autophagy-related interventions. They suggested that the missed co-primary endpoint could still lead to conditional marketing authorization, with a follow-up trial reinforcing the outcome.<stembedurl>https://stocktwits.com/tby24/message/636164840</stembedurl>Another user said, “I think there is a 40% chance of an opinion, 60% chance we, among some others, are not mentioned at all.”<stembedurl>https://stocktwits.com/keyeaster/message/636164762</stembedurl>A third user said, “Actually, rejection is easy, EMA had everything they needed, it would have been very easy for them just looking at data and they would have said no before oral explanation. SO THERE IS ONLY ONE OPTION LEFT::APPROVAL.”<stembedurl>https://stocktwits.com/DK_72/message/636124008</stembedurl><a href="https://stocktwits.com/symbol/AVXL">Anavex’s stock</a> has declined 33% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

 In this photo illustration, an Anavex Life Sciences Corp. logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Anavex Stock Just Logged Its Worst Selloff In 2 Years — What Does EMA’s Oral Explanation Week Mean For Its Alzheimer’s Drug?

The selloff comes as blarcamesine completed its oral explanation during the EMA’s Nov. 10–13 review window.

Anavex Life Sciences (NASDAQ:AVXL) Shares Down 6.7% - What's Next?

Anavex Life Sciences (NASDAQ:AVXL) Stock Price Down 6.7% - What's Next...

Stock Traders Purchase Large Volume of Anavex Life Sciences Put Options (NASDAQ:AVXL)

Anavex Life Sciences Corp. (NASDAQ:AVXL - Get Free Report) was the recipient of some unusual options trading activity on Monday. Investors bought 10,341 put options on the company. This represents an...

<ul class="summary-bullets"><li>The Committee for Medicinal Products for Human Use, or CHMP, provides recommendations to EMA on human medicines, which the agency uses to approve or reject a drug.</li><li>Anavex submitted an application to the EMA for Blarcamesine in November 2024 based on data from a Phase 2b/3 trial, and the agency subsequently accepted it in December.&nbsp;</li><li>If the application is approved, it would allow Blarcamesine to be marketed in all EU member states.</li></ul>Shares of Anavex Life Sciences (AVXL) were in the spotlight on Monday as retail investors contemplated the possibilities of a positive take from a European Medicines Agency (EMA) committee for the company’s Alzheimer’s drug Blarcamesine.The Committee for Medicinal Products for Human Use, or CHMP, provides recommendations to the agency on human medicines, which the agency uses to approve or reject a drug. On Monday, CHMP <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.ema.europa.eu/en/documents/agenda/agenda-chmp-meeting-10-13-november-2025_en.pdf">included</a> Blarcamesine on its agenda for oral explanations and regulatory review during the session scheduled from November 10 to 13. The oral explanation for Blarcamesine is scheduled for Nov. 11, 2025, at 2:00 p.m.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>A Stocktwits user is keenly awaiting the statement from Anavex.<stembedurl>https://stocktwits.com/DipperDoo/message/635619033</stembedurl>Another user expressed hope that the committee would be convinced of the drug’s importance following the oral presentation.<stembedurl>https://stocktwits.com/Cresskill198/message/635618141</stembedurl>AVXL shares were down 9% at the time of writing. On Stocktwits, overall retail sentiment around <a href="https://stocktwits.com/symbol/AVXL">AVXL stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘high’ levels.<figure class="image"><img style="aspect-ratio:587/57;" src="data:image/png;base64,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" width="587" height="57" alt="AVXL's Sentiment Meter and Message Volume as of 1:06 p.m. ET on Nov. 10, 2025 | Source: Stocktwits"><figcaption>AVXL's Sentiment Meter and Message Volume as of 1:06 p.m. ET on Nov. 10, 2025 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Anavex’s Application</h2>Anavex submitted an application to the EMA for Blarcamesine in November 2024 based on data from a Phase 2b/3 trial, and the agency subsequently accepted it in December. If the application is approved, it would allow Blarcamesine to be marketed in all EU member states.Last month, Spirit of the Coast Analytics <a href="https://stocktwits.com/news-articles/markets/equity/anavex-life-sciences-stock-sparks-retail-banter-on-hopes-of-ema-conditional-nod-for-alzheimer-s-drug-big-pharma-tie-up/cLGP67oR3po">noted</a> that Blarcamesine’s existing Phase 2b/3 data, while limited in sample size and missing one co-primary endpoint, showed statistically strong results and sustained efficacy over 192 weeks in long-term studies. According to the analyst, the company is “likely” positioned for approval by the EMA in Q4 2025 or Q1 2026. &nbsp;AVXL stock is down by 38% this year and by about 28% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/ifrx-stock-soars-pre-market-after-experimental-drug-shows-promise-in-treating-chronic-skin-diseases/cLPcS62RE2E">IFRX Stock Soars Pre-Market After Experimental Drug Shows Promise In Treating Chronic Skin Diseases</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

Esperion’s stock (ESPR) has risen 40.5% so far in 2025. (Representative Image: Getty Images)

AVXL Stock Draws Retail Attention Ahead Of Company’s Meeting With EMA Committee

On Monday, CHMP included Blarcamesine on its agenda for oral explanations and regulatory review during the session scheduled from November 10 to 13.

Anavex Life Sciences (NASDAQ:AVXL) Reaches New 1-Year Low - What's Next?

Anavex Life Sciences (NASDAQ:AVXL) Reaches New 1-Year Low - Here's Why...

<ul class="summary-bullets"><li>Spirit of the Coast Analytics said Anavex’s Alzheimer’s drug Blarcamesine is likely to gain conditional marketing authorization (CMA) from the European Medicines Agency, citing strong long-term efficacy data despite limited trial size.</li><li>The report projected tens of billions in peak sales potential and said Anavex would likely require a big-pharma partnership to achieve full commercialization.</li><li>On Stocktwits, traders praised the analysis as “best in class,” with some predicting off-label use across other dementia types and urging patience for long-term gains.</li></ul>Anavex Life Sciences shares drew some retail chatter on Tuesday after a new report from Spirit of the Coast Analytics projected that the company’s lead Alzheimer’s drug, Blarcamesine, could secure conditional approval in Europe and attract a major pharmaceutical partner to accelerate commercialization.<h2 class="st-heading-2">EMA Conditional Approval Expected</h2>Spirit of the Coast Analytics&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.sotcanalytics.com/update-compendium-2025#h.j7yb7yv7gs20">said</a> it believes Blarcamesine is “likely (though not definitive)” to receive conditional marketing authorization (CMA) from the European Medicines Agency (EMA). The report said the EMA often prefers granting conditional approval rather than outright denial for drugs addressing major unmet medical needs, particularly when data show large effect sizes.Analysts noted that Blarcamesine’s existing Phase 2b/3 data, while limited in sample size and missing one co-primary endpoint, showed statistically strong results and sustained efficacy over 192 weeks in long-term studies. The report emphasized that any conditional approval would reflect “incomplete” data, not doubts over validity.<h2 class="st-heading-2">Market Potential And Pricing Forecasts</h2>The report projected that Blarcamesine could capture up to 40% market share among early-stage Alzheimer’s patients across the U.S. and Europe, translating into tens of billions in potential revenue at peak.Spirit of the Coast estimated that the drug’s price could range between $10,000 and $18,200 per year in the U.S. and $8,000 and $14,000 in Europe, based on quality-adjusted life year (QALY) analysis. The analysts said the drug’s oral delivery, strong safety profile, and lack of complex monitoring requirements would support broad adoption and payer acceptance.<h2 class="st-heading-2">Partnership Pathway Viewed As Essential</h2>The report said Anavex “almost certainly requires a big-pharma partnership” to achieve its commercial potential. Analysts projected a possible multi-billion-dollar upfront payment with tiered royalty milestones under such a deal, noting that large pharmaceutical companies would likely seek to collaborate given the drug’s market opportunity and safety data.The report also said a partnership could accelerate regulatory engagement and manufacturing scale-up, allowing Anavex to compete more effectively against higher-priced monoclonal antibody therapies such as Leqembi and Kisunla.<h2 class="st-heading-2">Stocktwits Traders See Upside But Cautious On Long-Term Gains</h2>On Stocktwits, retail sentiment for Avanex was ‘bearish’ amid ‘normal’ message volume.One user called the analysis “best in class,” saying it highlighted “super-massive potential” for Blarcamesine, including off-label use in other dementias, and urged investors to “strap in” for the long term rather than selling early.<stembedurl>https://stocktwits.com/Veliger/message/633171391</stembedurl>Another user said the projections seemed “mathematically sound” but warned of a “fantasyland vibe,” estimating a 90% chance of approval and noting that retail investors’ gains may hinge on whether Anavex opts for a partnership or a buyout.<stembedurl>https://stocktwits.com/ItsThrillhouse/message/633175141</stembedurl><a href="https://stocktwits.com/symbol/AVXL">Avanex’s stock</a> has declined 13% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Avanex’s stock has declined 13% so far in 2025. (Photo credit: Getty Images)

Anavex Life Sciences Stock Sparks Retail Banter On Hopes Of EMA Conditional Nod For Alzheimer's Drug, Big Pharma Tie-Up

The report projected tens of billions in peak sales potential and said Anavex would likely require a big-pharma partnership to achieve full commercialization.

Anavex Life Sciences (AVXL) on Thursday said that its investigational drug achieved its primary endpoint in a mid-stage trial and demonstrated safety and tolerability in adults with Schizophrenia.Shares of the company soared 9% in Thursday’s pre-market session.The company <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/02/3160275/29248/en/Anavex-Life-Sciences-Announces-Positive-Topline-Results-from-Phase-2-Study-of-ANAVEX-3-71-for-the-Treatment-of-Schizophrenia.html">said</a> that the safety profile of ANAVEX3-71 was consistent with previous studies in healthy volunteers, and no serious treatment-emergent adverse events were reported in the study.The company is evaluating the drug in the treatment of Schizophrenia, a persistent and often disabling mental illness impacting how a person thinks, feels, and behaves, and affects nearly 24 million people worldwide. According to Anavex, the illness impacts 2.8 million people in the U.S. alone.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/AVXL">AVXL stock</a> jumped from ‘neutral’ to ‘bullish’ over the past 24 hours, while message volume stayed at ‘high’ levels.Anavex also said on Thursday that encouraging trends were observed in biomarkers of Schizophrenia in the study that support continued development. This includes a reduced glial fibrillary acidic protein in patients receiving ANAVEX3-71 compared to placebo.GFAP is a marker of neuroinflammation, and a reduction in it suggests a potential disease-modifying effect that may become more pronounced with longer treatment durations, the company said.The company on Thursday also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.globenewswire.com/news-release/2025/10/02/3160281/29248/en/Anavex-Life-Sciences-Announces-Successful-Development-of-Once-Daily-Oral-Tablet-Formulation-for-the-ANAVEX-3-71-Program.html">announced</a> the successful development of a once-daily oral tablet formulation for the ANAVEX3-71 program. The tablet exhibits superior pharmacokinetics compared to the current immediate-release oral capsule, enabling once-daily dosing, it added.AVXL stock is down 16% this year but up approximately 59% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/rivian-slashes-full-year-delivery-guidance-after-drop-in-q3-figures/chCrfpbR3OH">Rivian Slashes Full-Year Delivery Guidance After Drop In Q3 Figures</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Anavex Life Sciences Stock Just Shot Up 7% Today – Here’s An Important Update

The company said that its investigational drug for Schizophrenia achieved its primary endpoint in a mid-stage trial.

Anavex Life Sciences Corp. is a clinical stage biopharmaceutical company, which engages in the development of different therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases. Its lead compound, ANAVEX2-73, is being developed to treat Alzheimer's and Parkinson's disease and central nervous system diseases, including Rett syndrome. The company was founded by Harvey Lalach and Athanasios Skarpelos on January 23, 2004 and is headquartered in New York, NY.

Anavex Life Sciences Corporation

Will NVIDIA ($NVDA) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

AVXL
Anavex Life Sciences Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest AVXL News

AVXLAnavex Life Sciences Corp